A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer

NCT ID: NCT06202248

Last Updated: 2025-12-02

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-12
• Study Completion Date: 2027-06-30

Brief Summary

This is a multi-center clinical study enrolling up to 10 participants. The purpose of this study is to assess the feasibility and safety of intratumoral DaRT seeds implantation for the treatment of locally recurrent prostate cancer. Secondary objectives are to 1. To evaluate feasibility of interstitial radiotherapy using DaRT seeds.

Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging [Timeframe: immediately following the insertion procedure 2. To assess the impact of DaRT seeds on patient reported quality of life.

Detailed Description

This study is a prospective multicenter, single arm, open label , interventional clinical study to assess the feasibility and safety of intratumoral Alpha DaRT seeds for the treatment of men with non metastatic locally recurrent prostate cancer.

Diffusing Alpha emitters Radiation Therapy (DaRT). Treatment will be delivered through radioactive sources [Ra-224 containing Stainless steel 316LVM tubes- (Alpha DaRT seeds)] inserted into the tumors.

The purpose of this study is to assess the feasibility and safety of intratumoral DaRT seeds implantation for the treatment of locally recurrent prostate cancer. The secondary objectives is 1. To evaluate feasibility of interstitial radiotherapy using DaRT seeds.

Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging [Timeframe: immediately following the insertion procedure 2. To assess the impact of DaRT seeds on patient reported quality of life.

Conditions

Non-metastatic Prostate Cancer; Locally Recurrent Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DaRT Seeds

Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

Group Type: EXPERIMENTAL

Experimental: DaRT seeds

Intervention Type: DEVICE

Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

Interventions

Experimental: DaRT seeds

Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed locally recurrent prostate adenocarcinoma cancer confined to at least 1 hemi-gland with concordant pathology and imaging findings within 6 months prior to consenting
• Targetable lesion by either PSMA PET-CT according to PERCIST v1.0 or by multiparametric MRI according RECIST v1.1
• Patient being considered for focal salvage brachytherapy
• Lesion size ≤ 3 cm in the longest diameter
• Target lesion technically amenable for full tumor coverage with the Alpha DaRT seeds
• Pre-salvage PSA level (rPSA) below <10 ng/ml
• Age ≥ 18 years old
• ECOG Performance Status Scale ≤ 2
• Subjects' life expectancy is more than 6 months
• Negative metastatic workup on at least standard imaging (CT CAP and bone scan). Other metastatic screening studies allowed in lieu of standard imaging including multiparametric MRI prostate/whole body, PSMA PET, F18 PET or Axumin PET within 3 months before visit 0
• Platelet count ≥100,000/mm3
• Subjects are willing and able to sign an informed consent form.

Exclusion Criteria

• N1 or M1 disease
• Prior TURP or prostate surgery
• Inability to undergo multiparametric MRI (i.e. permanent implanted device incompatible with MRI)
• Inability to undergo general or spinal anesthesia
• Prior androgen deprivation therapy or systemic chemotherapy for prostate cancer within 3 months before visit 0.
• Previous diagnosis of other malignancy < 3 years of enrollment (excluding non-melanomatous skin cancer)
• Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT
• High probability of protocol non-compliance (in opinion of investigator)
• Subjects not willing to sign an informed consent
• Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Alpha Tau Medical LTD.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tomer Charas, MD

Role: PRINCIPAL_INVESTIGATOR

Radiotherapy unit at Rambam Health Care Campus, Israel

Locations

RAMBAM Health Care Campus

Haifa, , Israel

Site Status: RECRUITING

Countries

Israel

Central Contacts

Liron Dimnik

Role: CONTACT

LironD@alphatau.com

+972542688602

Aviya Hoida

Role: CONTACT

aviyah@alphatau.com

+972547869466

Facility Contacts

Tomer Charas, MD

Role: primary

t_charas@rambam.health.gov.il

+972502062073

Guy Froumin

Role: backup

g_froumin@rambam.health.gov.il

Other Identifiers

CTP-PRST-00

Identifier Type: -

Identifier Source: org_study_id